No CrossRef data available.
Article contents
Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable
Published online by Cambridge University Press: 31 May 2024
Abstract
Glucagon-like peptide-1 receptor agonists are effective for treating obesity, but the high cost of these medications endangers the financial viability of our health care system. To ensure that these drugs are available to Medicare beneficiaries, pharmaceutical manufacturers must lower their prices.
Keywords
- Type
- Columns: Health Policy Portal
- Information
- Copyright
- © The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics
Footnotes
About This Column
Aaron Kesselheim serves as the editor for Health Policy Portal. Dr. Kesselheim is the JLME editor-in-chief and director of the Program On Regulation, Therapeutics, And Law at Brigham and Women’s Hospital/Harvard Medical School. This column features timely analyses and perspectives on issues at the intersection of medicine, law, and health policy that are directly relevant to patient care. If you would like to submit to this section of JLME, please contact Dr. Kesselheim at akesselheim@bwh.harvard.edu.